Low-molecular-weight heparins in coronary arterial thrombus disease: A review of the literature

Pharmacotherapy

Volumn 18, Issue 2 I, 1998, Pages 265-272

  Rodman, Daniel P ^a,b  

^a Owen Healthcare Inc   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PARNAPARIN; TICLOPIDINE;

ACUTE HEART INFARCTION; BLEEDING; CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY THROMBOSIS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG COST; DRUG EFFICACY; HUMAN; MAJOR CLINICAL STUDY; PHASE 1 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REVIEW; STENT; SUBCUTANEOUS DRUG ADMINISTRATION; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS;

ANTICOAGULANTS; CLINICAL TRIALS; CORONARY DISEASE; CORONARY THROMBOSIS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS;

EID: 0031941765     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Bergqvist D, Burmark US, Frisell J, et al. Low molecular weight heparin once daily compared with conventional low dose heparin twice daily: a prospective double-blind multicentre trial on prevention of postoperative thrombosis. Br J Surg 1986;73:204-8.
2. Turpie AG, Levine MN, Hirsh J, et al. A randomized controlled trial of a low-molecular weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery. N Engl J Med 1986;315:925-9.
3. Faivre R, Neuhart E, Kieffer Y, Toulemonde F, Bassand JP, Mavrat JP. Subcutaneous administration of a low molecular weight heparin CY222 compared with subcutaneous administration of standard heparin in patients with acute deep vein thrombosis [abstr]. Thromb Haemost 1987;58(suppl):430.
4. Caen JP. A randomized double-blind study between a low molecular weight heparin Kabi 2165 and standard heparin in the prevention of deep venous thrombosis in general surgery. Thromb Haemost 1988;59:216-20.
5. European Fraxiparin Study Group. Comparison of a low molecular weight heparin and unfractionated heparin for the prevention of deep vein thrombosis in patients undergoing abdominal surgery. Br J Surg 1988;75:1058-63.
6. Ockelford PA, Patterson J, Johns AS. A double-blind randomized placebo controlled trial of thromboprophylaxis in major elective general surgery using once daily injections of a low molecular weight heparin fragment (Fragmin). Thromb Haemost 1989;62:1046-9.
7. Estoppey D, Hochreiter J, Breyer HG, et al. ORG 10172 (Lomoparin) versus heparin-DHE in the prevention of thromboembolism in total hip replacement - a multicentre trial [abstr]. Thromb Haemost 1989;62(suppl):356.
8. Bergqvist D, Kettunen K, Fredin H, et al. Thromboprophylaxis in hip fracture patients - a prospective randomized comparative study between ORG 10172 and dextran. Surgery 1991;109:617-22.
9. Nurmohamed MT, Rosendaal FR, Buller HR, et al. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis. Lancet 1992;340:152-6.
10. Bergqvist D, Matzsch T, Burmark US, et al. Low molecular weight heparin given the evening before surgery compared with conventional low dose heparin in prevention of thrombosis. Br J Surg 1988;75:888-91.
11. Dahan R, Houlbert D, Caulin C, et al. Prevention of deep vein thrombosis in elderly medical patients by a low molecular weight heparin: a randomized double-blind trial. Haemostasis 1986;16:159-64.
12. Levine MN, Hirsh J, Gent M, et al. Prevention of deep vein thrombosis after elective hip surgery. A randomized trial comparing low molecular weight heparin with standard unfractionated heparin. Ann Intern Med 1991;114:545-51.
13. Colwell CW, Spiro TE, Trowbridge AA, et al. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement. J Bone Joint Surg 1994;76-A:3-14.
14. Simonneau G, Charbonnier B, Decousus H, et al. Subcutaneous low-molecular-weight heparin compared with continuous intravenous unfractionated heparin in the treatment of proximal deep vein thrombosis. Arch Intern Med 1993;153:1541-6.
15. Levine M, Gent M, Hirsh J, et al. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med 1996;334: 677-81.
16. Koopman MMW, Prandoni P, Piovella F, et al. Treatment of venous thrombosis with intravenous unfractionated heparin administered in the hospital as compared with subcutaneous low-molecular-weight heparin administered at home. N Engl J Med 1996;334:682-7.
17. Bergqvist D, Burmark US, Flordall PA, et al. Low molecular weight heparin started before surgery as prophylaxis against deep venous thrombosis: 2500 versus 5000 XaI units in 2070 patients. Br J Surg 1995;82:496-501.
18. Lindmarker P, Holmstrom M, Granqvist S, Johnsson H, Lockner D. Comparison of once-daily subcutaneous fragmin with continuous intravenous heparin in the treatment of deep vein thrombosis. Thromb Haemost 1994;72:186-90.
19. Alhenc-Gelas M, Jestin-Le Guernic C, Vitoux JF, et al. Adjusted versus fixed doses of the low-molecular-weight heparin fragmin in the treatment of deep vein thrombosis. Thromb Haemost 1994;71:698-702.
20. Holmstrom MC, Granquist S, Tornebohm BE, Lockner D. Fragmin once or twice daily subcutaneously in the treatment of deep venous thrombosis of the leg. Thromb Res 1992;67: 49-55.
21. Ginsberg JS. Management of venous thromboembolism. N Engl J Med 1996;335:1816-28.
22. Hyers TM, Hull RD, Weg JG. Antithrombotic therapy for venous thromboembolic disease. Chest 1995;108(suppl): 335S-51.
23. Hoppensteadt D, Walenga JM, Fareed J. Low molecular weight heparins: an objective overview. Drugs Aging 1992;2:406-22.
24. Boneu B, Buchanan MR, Cade JF, et al. Effects of heparin, its low molecular weight fractions and other glycosaminoglycans on thrombus growth in vivo. Thromb Res 1985;40:81-9.
25. Bara L, Leizorovicz A, Picolet H, Samama M. Correlation between anti-Xa occurrence of thrombosis and haemorrhage in post-surgical patients treated with either Logiparin (LMWH) or unfractionated heparin. Thromb Res 1992;65:641-50.
26. Nieuwenhuis HK, Albada J, Banga JD, Sixma JJ. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood 1991;78:2337-43.
27. Melandri G, Branzi A, Semprini F, et al. Effects of two dosages of subcutaneous low molecular weight heparin (panaparin) and of unfractionated heparin of fibrin formation and lipolysis in acute myocardial infarction. Thromb Res 1992;66(2/3): 141-50.
28. Nesvold A, Kontny F, Abilgaard U, Dale J. Safety of high doses of low molecular weight heparin (fragmin) in acute myocardial infarction. A dose-finding study. Thromb Res 1991;64:579-87.
29. Turpie AG, Robinson JG, Doyle DJ, et al. Comparison of high-dose with low-dose subcutaneous heparin to prevent left ventricular mural thrombus in patients with subacute transmural anterior myocardial infarction. N Engl J Med 1989; 320:352-7.
30. Faxon DP, Spiro TE, Minor S, et al. Low molecular weight heparin in prevention of restenosis after angioplasty. Results of enoxaparin restenosis (ERA) trial. Circulation 1994;90:908-14.
31. Holmes DR, Schwartz RS, Webster MW. Coronary restenosis: what have we learned from angiography? J Am Coll Cardiol 1991;17:14B-22.
32. Fajadet J, Carvalho H, Jordan C, et al. Reduction of early complications after Gianturco-Roubin coronary stenting using a new anticoagulant protocol [abstr]. Eur Heart J 1994;15:536.
33. Pan M, Suarez de Lezo J, Medina A, et al. Comparison of two antithrombotic strategies after Palmaz-Schatz stent implantation. Is milder the more effective? [abstr]. Eur Heart J 1995;16:250.
34. Morice MC, Bourdonnec C, Valeix B, et al. Coronary stenting without warfarin. Phase II [abstr]. Eur Heart J 1994;15:536.
35. Fernandez-Aviles F, Alonso J, Duran JM, et al. Absence of bleeding and subacute occlusion after Palmaz-Schatz coronary stenting using a new antithrombotic regimen [abstr]. J Am Coll Cardiol 1995;25:196A.
36. Hearn JA, King SB, Douglas JS, et al. Clinical and angiographic outcomes after coronary artery stenting for acute or threatened closure after percutaneous transluminal coronary angioplasty: initial results with a balloon-expandable, stainless steel design. Circulation 1993;88:2086-96.
37. Lincoff AM, Topol EJ, Chapekis AT, et al. Intracoronary stenting compared with conventional therapy for abrupt closure complicating coronary angioplasty: a matched case-control study. J Am Coll Cardiol 1993;21:866-75.
38. Danchin N, Daclin V, Juilliere Y, et al. Changes in patient treatment after abrupt closure complicating percutaneous transluminal coronary angioplasty: a historic perspective. Am Heart J 1995;130:1158-63.
39. Gurfinkel EP, Manos EJ, Mejail RI, et al. Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia. J Am Coll Cardiol 1995;26:313-18.
40. FRISC Study Group. Low-molecular-weight heparin during instability in coronary artery disease. Lancet 1996;347:561-8.
41. Cohen M, Demers C, Gurfinkel E, et al. A comparison of low-molecular weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med 1997;337: 447-52.
42. Sobel M, Bird KE, Tyler-Cross R, et al. Heparins designed to specifically inhibit platelet interactions with von Willebrand factor. Circulation 1996;93:992-9.
43. Hirsh J, Levine MN. Low molecular weight heparin: laboratory properties and clinical evaluation. Eur J Surg 1994;571(suppl): 9-22.
44. Salzman E, Rosenberg R, Smith M, Lindon J, Favreau L. Effect of heparin and heparin fractions on platelet aggregation. J Clin Invest 1980;65:64-73.
45. Sobel M, McNeill PM, Carlson PL, et al. Heparin inhibition of von Willebrand factor-dependent platelet function in vitro and in vivo. J Clin Invest 1991;87:1787-93.
46. Fabris F, Fussi F, Casonato A, et al. Normal and low molecular weight heparins: interaction with human platelets. Eur J Clin Invest 1983;13:135-9.
47. Becker RC, Ansell J. Antithrombotic therapy. An abbreviated guide for clinicians. Arch Intern Med 1995;155:149-61.
48. Hirsch J, Raschke R, Warkentin TE, Dalen JE, Deykin D, Poller L. Heparin: mechanism of action, pharmacokinetics, dosing considerations, monitoring, efficacy, and safety. Chest 1995;108(suppl):258S-75.
49. Hull RD, Raskob GE, Hirsh J, et al. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986;315:1109-14.
50. Bara L, Billauad E, Gramond G. Comparative pharmacokinetics of low molecular weight heparin (PK 10169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb Res 1985;39:631-6.